Black Diamond Therapeutics, Inc.
NASDAQ:BDTXBiotechnology
-$0.04 today
- Market cap
- $82.18M
- Beta
- 3.23
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$0.75
Volume 0.60M
Average 1.31M
BDTX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Black Diamond Therapeutics, Inc.NASDAQ: BDTX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $27K fell 69.0% year over year, behind the -23.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 59.1% from the prior quarter. Over 3 fiscal years it compounded at -13.8% a year.
Context
- Depreciation & amortization amounted to 0.5% of revenue in FY2025.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -69.0% toward the trailing-twelve-month pace of -23.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 325K USD
- Year-over-year change
- -5.2%
- 4-year CAGR
- +12.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 325K | -5.2% |
| FY2024 | 2024-12-31 | 343K | -21.5% |
| FY2023 | 2023-12-31 | 437K | -14.0% |
| FY2022 | 2022-12-31 | 508K | +147.8% |
| FY2021 | 2021-12-31 | 205K | — |
Depreciation & Amortization vs competitors
How BDTX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -23.0% is the 7th highest of 11, against a peer median of -14.7%.
- Over three fiscal years its annual growth of -13.8% compares with a peer median of +0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.81M USD | -13.0% | +11.0% | 3469.8% | |
| LTM Mar 2026 | $4.95M USD | +56.5% | +19.6% | 7.2% | |
| LTM Mar 2026 | $3.62M USD | +20.6% | -8.0% | 24.9% | |
| FY2025 | €3.22M EUR | -38.0% | +23.8% | 71.9% | |
| LTM Mar 2026 | $3.13M USD | -28.6% | +0.0% | 27.9% | |
| LTM Mar 2026 | $2.84M USD | -8.0% | -25.0% | 10.1% | |
| LTM Mar 2026 | $718K USD | -3878.9% | — | — | |
| LTM Mar 2026 | $531.13K USD | +15.1% | -4.3% | — | |
| LTM Mar 2026 | $265K USD | -23.0% | -13.8% | — | |
| LTM Mar 2026 | $226K USD | -16.3% | +27.5% | 383.1% | |
| LTM Mar 2026 | $103K USD | -59.6% | -11.6% | 0.2% | |
| Peer median (excluding BDTX) | — | -14.7% | +0.0% | 26.4% | |
Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (125.6M) | (91.17M) | (82.44M) | (69.68M) | 22.37M |
| Depreciation & Amortization | 205K | 508K | 437K | 343K | 325K |
| Deferred Income Tax | 2.18M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.04M | 12.2M | 9.6M | 10.63M | 6.63M |
| Change in Working Capital | 7.02M | (9.9M) | 3.69M | (2.69M) | (8.73M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.57M | (2.23M) | 597K | 1.68M | (3.43M) |
| Other Working Capital | 5.45M | (7.67M) | 3.09M | (4.38M) | (5.3M) |
| Other Non-Cash Items | 2.01M | 3.28M | 2M | (905K) | 9.02M |
| Operating Cash Flow | (100.15M) | (85.08M) | (66.72M) | (62.3M) | 29.61M |
| Capital Expenditures | (2.71M) | (192K) | (33K) | 0 | 0 |
| Acquisitions (Net) | 2.7M | 9K | 0 | 94K | 27K |
| Purchases of Investments | (49.51M) | (60.14M) | (61.89M) | (122.88M) | (164.03M) |
| Sales of Investments | 182.83M | 113.69M | 78.17M | 139.75M | 119.02M |
| Other Investing Activities | (2.7M) | 0 | 95K | 0 | 74K |
| Investing Cash Flow | 130.61M | 53.37M | 16.35M | 16.97M | (44.91M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 729K | 177K | 71.85M | 24.49M | (146K) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 82K | 1.05M | 0 |
| Financing Cash Flow | 729K | 177K | 71.93M | 25.55M | (146K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 31.19M | (31.54M) | 21.56M | (19.79M) | (15.44M) |
| Free Cash Flow | (102.86M) | (85.27M) | (66.75M) | (62.3M) | 29.61M |
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Intrinsic Alpha fair value
Locked
Current Price
$1.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.